EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
Rhea-AI Summary
EUDA Health (NASDAQ:EUDA), a Singapore-based non-invasive healthcare provider focused on Singapore, Malaysia and China, received notice on May 28, 2026 that it has regained compliance with Nasdaq’s Minimum Market Value of Listed Securities requirement.
EUDA’s MVLS was at least $35 million for ten consecutive business days from May 13–27, 2026, restoring eligibility for continued listing on the Nasdaq Capital Market.
Positive
- Regained Nasdaq MVLS compliance with ≥$35M for 10 consecutive days
- Maintains eligibility for continued listing on the Nasdaq Capital Market
Negative
- Previously failed to maintain $35M MVLS for 32 consecutive business days
- Received Nasdaq MVLS deficiency notice on April 23, 2026
News Market Reaction – EUDA
In the Jun 1 session, EUDA declined 7.38%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | R&D program approval | Positive | -6.7% | Shenzhen Inno TCR-T therapy R&D project approval with potential funding support. |
| Apr 27 | MVLS deficiency notice | Negative | +21.1% | Nasdaq notice that EUDA failed MVLS $35M requirement over 32 days. |
| Mar 19 | Reverse stock split | Negative | -15.2% | Announcement of 1-for-20 reverse split to consolidate ordinary shares. |
| Mar 04 | Warrant repurchase | Positive | -2.7% | Repurchase and cancellation of Streeterville warrant removing up to 2,000,000 shares. |
| Jan 15 | Warrant amendment | Negative | -4.2% | Reduction of warrant exercise and forced-exercise prices under Streeterville agreement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent EUDA news often saw price moves that diverged from the apparent sentiment of the announcement, especially for regulatory and capital-structure items.
Over the past six months, EUDA has focused on capital structure, compliance, and strategic collaborations. A 1-for-20 reverse split on Mar 23, 2026 and multiple warrant amendments highlighted ongoing balance-sheet work. The company later repurchased and cancelled a Streeterville warrant, removing up to 2,000,000 potential shares. Regulatory pressure surfaced with an MVLS deficiency notice on Apr 23, 2026, even as EUDA announced a Shenzhen Inno TCR-T cell therapy R&D program. Today’s MVLS compliance notice directly follows that earlier deficiency disclosure.
Key Terms
minimum market value of listed securities regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of
On May 28, 2026, the Company received a written notice from Nasdaq stating that the Company’s Market Value of Listed Securities has been
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over approximately 1.8 billion people across the region which are experiencing significant demographic shifts as more than approximately
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
For investor and media inquiries, please contact:
Christensen Advisory
Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com
